Mealey's (June 16, 2020, 4:44 PM EDT) -- DENVER — Genentech Inc. on June 12 petitioned the 10th Circuit U.S. Court of Appeals to rehear or rehear en banc arguments that claims about the company underfilling vials of the breast cancer drug Herceptin are preempted by federal law (In re: Genentech, Inc., Herceptin [Trastuzumab] Marketing and Sales Practices Litigation, No. 19-5035, 10th Cir.)....